论文信息 - Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma - 字舞流文

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

O. Decaux | P. Moreau | H. Avet-Loiseau | X. Leleu | A. Schmitt | T. Facon | V. Richez | F. Offner | P. Rodon | O. Fitoussi | F. Kuhnowski | M. Roussel | L. Karlin | A. Perrot | M. Tiab | C. Araujo | P. Lenain | E. Voog | J. Eisenmann | C. Hulin | M. Kyheng | J. Malfuson | S. Rigaudeau | L. Voillat | N. Meuleman | M. Chrétien | S. Guidez | P. Bourquard | M. Petillon | J. Fontan | A. Jaccard | S. Cereja | B. Kolb | A. Bobin | Alain Duhamel | V. Dorvaux | D. Roos-Weil | K. Belhadj-Merzoug | J. Frayfer | Cécile Gruchet-Merouze | C. Humbrecht-Kraut

[1] G. Morgan,et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial , 2019, The Lancet. Oncology.

[2] H. Goldschmidt,et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) , 2018, Leukemia.

[3] M. Dimopoulos,et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. , 2018, Blood.

[4] O. Decaux,et al. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) , 2015 .

[5] J. Mary,et al. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. , 2015, Blood.

[6] Michael L. Wang,et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. , 2012, Blood.

[7] M. Beksac,et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.

[8] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.

[9] S. Demo,et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. , 2005, Blood.

[10] M. Dimopoulos,et al. Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible , NDMM patients Running title : KMP vs VMP for newly diagnosed multiple myeloma , 2019 .

[11] H. Goldschmidt,et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. , 2016, The Lancet. Oncology.